Literature DB >> 12761093

The Mycobacterium tuberculosis recombinant 27-kilodalton lipoprotein induces a strong Th1-type immune response deleterious to protection.

Avi-Hai Hovav1, Jacob Mullerad, Liuba Davidovitch, Yolanta Fishman, Fabiana Bigi, Angel Cataldi, Herve Bercovier.   

Abstract

Th1 immune response is essential in the protection against mycobacterial intracellular pathogens. Lipoproteins trigger both humoral and cellular immune responses and may be candidate protective antigens. We studied in BALB/c mice the immunogenicity and the protection offered by the recombinant 27-kDa Mycobacterium tuberculosis lipoprotein and the corresponding DNA vaccine. Immunization with the 27-kDa antigen resulted in high titers of immunoglobulin G1 (IgG1) and IgG2a with a typical Th1 profile and a strong delayed hypersensitivity response. A strong proliferation response was observed in splenocytes, and significant nitric oxide production and gamma interferon secretion but not interleukin 10 secretion were measured. Based on these criteria, the 27-kDa antigen induced a typical Th1-type immune response thought to be necessary for protection. Surprisingly, in 27-kDa-vaccinated mice (protein or DNA vaccines) challenged by M. tuberculosis H37Rv or BCG strains, there was a significant increase in the numbers of CFU in the spleen compared to that for control groups. Furthermore, the protection provided by BCG or other mycobacterial antigens was completely abolished once the 27-kDa antigen was added to the vaccine preparations. This study indicates that the 27-kDa antigen has an adverse effect on the protection afforded by recognized vaccines. We are currently studying how the 27-kDa antigen modulates the mouse immune response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12761093      PMCID: PMC155707          DOI: 10.1128/IAI.71.6.3146-3154.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  Lipoprotein access to MHC class I presentation during infection of murine macrophages with live mycobacteria.

Authors:  O Neyrolles; K Gould; M P Gares; S Brett; R Janssen; P O'Gaora; J L Herrmann; M C Prévost; E Perret; J E Thole; D Young
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

2.  Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

Authors:  A Weinrich Olsen; L A van Pinxteren; L Meng Okkels; P Birk Rasmussen; P Andersen
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

Review 3.  Lymphocyte polyclonal activation: a pitfall for vaccine design against infectious agents.

Authors:  B Reina-San-Martin; A Cosson; P Minoprio
Journal:  Parasitol Today       Date:  2000-02

4.  Analysis of human T-cell epitopes in the 19,000 MW antigen of Mycobacterium tuberculosis: influence of HLA-DR.

Authors:  A Faith; C Moreno; R Lathigra; E Roman; M Fernandez; S Brett; D M Mitchell; J Ivanyi; A D Rees
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

5.  Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major.

Authors:  Javier Cote-Sierra; Amin Bredan; Carmen M Toldos; Benoit Stijlemans; Lea Brys; Pierre Cornelis; Manuel Segovia; Patrick de Baetselier; Hilde Revets
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

6.  Immunization with components of two iron uptake ABC transporters protects mice against systemic Streptococcus pneumoniae infection.

Authors:  J S Brown; A D Ogunniyi; M C Woodrow; D W Holden; J C Paton
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

7.  The 19-kD antigen and protective immunity in a murine model of tuberculosis.

Authors:  V V Yeremeev; I V Lyadova; B V Nikonenko; A S Apt; C Abou-Zeid; J Inwald; D B Young
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

8.  Induction of direct antimicrobial activity through mammalian toll-like receptors.

Authors:  S Thoma-Uszynski; S Stenger; O Takeuchi; M T Ochoa; M Engele; P A Sieling; P F Barnes; M Rollinghoff; P L Bolcskei; M Wagner; S Akira; M V Norgard; J T Belisle; P J Godowski; B R Bloom; R L Modlin
Journal:  Science       Date:  2001-02-23       Impact factor: 47.728

9.  The gene encoding P27 lipoprotein and a putative antibiotic-resistance gene form an operon in Mycobacterium tuberculosis and Mycobacterium bovis.

Authors:  F Bigi; A Alito; M I Romano; M Zumarraga; K Caimi; A Cataldi
Journal:  Microbiology       Date:  2000-04       Impact factor: 2.777

10.  Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis.

Authors:  R N Coler; A Campos-Neto; P Ovendale; F H Day; S P Fling; L Zhu; N Serbina; J L Flynn; S G Reed; M R Alderson
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

View more
  20 in total

1.  Mitogenicity of the recombinant mycobacterial 27-kilodalton lipoprotein is not connected to its antiprotective effect.

Authors:  Avi-Hai Hovav; Liuba Davidovitch; Gabriel Nussbaum; Jacob Mullerad; Yolanta Fishman; Herve Bercovier
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

2.  Functional and evolutionary genomics of Mycobacterium tuberculosis: insights from genomic deletions in 100 strains.

Authors:  Anthony G Tsolaki; Aaron E Hirsh; Kathryn DeRiemer; Jose Antonio Enciso; Melissa Z Wong; Margaret Hannan; Yves-Olivier L Goguet de la Salmoniere; Kumiko Aman; Midori Kato-Maeda; Peter M Small
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-15       Impact factor: 11.205

3.  Gamma interferon and monophosphoryl lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine.

Authors:  Avi-Hai Hovav; Yolanta Fishman; Herve Bercovier
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  Evaluation of a recombinant BCG expressing antigen Ag85B and PPE protein Rv3425 from DNA segment RD11 of Mycobacterium tuberculosis in C57BL/6 mice.

Authors:  Jiu ling Wang; Ya qing Qie; Bing dong Zhu; Hong mei Zhang; Ying Xu; Qing zhong Wang; Jia zhen Chen; Wei Liu; Hong hai Wang
Journal:  Med Microbiol Immunol       Date:  2008-05-20       Impact factor: 3.402

Review 5.  Virulence factors of the Mycobacterium tuberculosis complex.

Authors:  Marina A Forrellad; Laura I Klepp; Andrea Gioffré; Julia Sabio y García; Hector R Morbidoni; María de la Paz Santangelo; Angel A Cataldi; Fabiana Bigi
Journal:  Virulence       Date:  2012-10-17       Impact factor: 5.882

6.  Lactoferrin modulation of IL-12 and IL-10 response from activated murine leukocytes.

Authors:  Shen-An Hwang; Katarzyna M Wilk; Yogesh A Bangale; Marian L Kruzel; Jeffrey K Actor
Journal:  Med Microbiol Immunol       Date:  2007-03-22       Impact factor: 3.402

7.  In vitro culture medium influences the vaccine efficacy of Mycobacterium bovis BCG.

Authors:  Manjunatha M Venkataswamy; Michael F Goldberg; Andres Baena; John Chan; William R Jacobs; Steven A Porcelli
Journal:  Vaccine       Date:  2011-12-18       Impact factor: 3.641

8.  Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection.

Authors:  Denise Morais da Fonseca; Célio Lopes Silva; Marina Oliveira e Paula; Edson Garcia Soares; Gilles Marchal; Cynthia Horn; Vânia Luiza Deperon Bonato
Journal:  Immunology       Date:  2007-04-13       Impact factor: 7.397

9.  Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles.

Authors:  Andreia P Soares; Thomas J Scriba; Sarah Joseph; Ryhor Harbacheuski; Rose Ann Murray; Sebastian J Gelderbloem; Anthony Hawkridge; Gregory D Hussey; Holden Maecker; Gilla Kaplan; Willem A Hanekom
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

10.  Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a Mycobacterial protein vaccine-adjuvant combination but not after coadministration of adjuvant alone.

Authors:  D Neil Wedlock; Michel Denis; Gavin F Painter; Gary D Ainge; H Martin Vordermeier; R Glyn Hewinson; Bryce M Buddle
Journal:  Clin Vaccine Immunol       Date:  2008-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.